We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

294 hedge funds and large institutions have $1.77B invested in BioCryst Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 113 increasing their positions, 85 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more call options, than puts

Call options by funds: $12.7M | Put options by funds: $6.52M

73% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 30

34% more capital invested

Capital invested by funds: $1.32B → $1.77B (+$450M)

33% more repeat investments, than reductions

Existing positions increased: 113 | Existing positions reduced: 85

10.6% more ownership

Funds ownership: 83.64% → 94.23% (+11%)

7% more funds holding

Funds holding: 274 → 294 (+20)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
294
Holders Change
+20
Holders Change %
+7.3%
% of All Funds
3.87%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
52
Increased
113
Reduced
85
Closed
30
Calls
$12.7M
Puts
$6.52M
Net Calls
+$6.18M
Net Calls Change
+$1.41M

Top Buyers

Rank Fund Capital Flow
1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$38M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$33.6M
3
UBS Group
UBS Group
Switzerland
+$29.9M
4
Morgan Stanley
Morgan Stanley
New York
+$28.2M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$26.1M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$39.1M
2
CP
Caligan Partners
New York
-$23M
3
Millennium Management
Millennium Management
New York
-$17.8M
4
Ameriprise
Ameriprise
Minnesota
-$15.3M
5
Alkeon Capital Management
Alkeon Capital Management
New York
-$14M
Name Holding Trade Value Shares
Change 		Change in
Stake
YIH
76
Y-Intercept (HK)
Hong Kong
$3.01M +$1.81M +194,230 +137%
EI
77
EAM Investors
California
$3M +$3.11M +334,347 New
DMKJ
78
David M. Knott Jr
$2.98M -$1.19M -127,375 -28%
Hudson Bay Capital Management
79
Hudson Bay Capital Management
Connecticut
$2.73M -$1.81M -193,907 -39%
Rafferty Asset Management
80
Rafferty Asset Management
New York
$2.7M +$444K +47,626 +19%
Federated Hermes
81
Federated Hermes
Pennsylvania
$2.67M +$1.06M +113,297 +61%
NRD
82
Nebula Research & Development
New York
$2.57M +$2.67M +286,509 New
Wells Fargo
83
Wells Fargo
California
$2.55M +$623K +66,847 +31%
Jane Street
84
Jane Street
New York
$2.5M -$1.93M -207,311 -43%
AllianceBernstein
85
AllianceBernstein
Tennessee
$2.47M – – –
DA
86
Doliver Advisors
Texas
$2.46M +$1.86M +200,000 +269%
BFM
87
Boothbay Fund Management
New York
$2.46M -$9.78M -1,050,094 -79%
Balyasny Asset Management
88
Balyasny Asset Management
Illinois
$2.26M -$3.11M -333,792 -57%
JG
89
Jain Global
New York
$2.16M +$2.24M +240,693 New
SG Americas Securities
90
SG Americas Securities
New York
$2.11M +$1.79M +192,036 +442%
SEI Investments
91
SEI Investments
Pennsylvania
$2M +$1.06M +113,776 +104%
Royal Bank of Canada
92
Royal Bank of Canada
Ontario, Canada
$1.99M +$1.48M +159,127 +251%
GCM
93
Graham Capital Management
Connecticut
$1.96M +$773K +82,981 +61%
DCM
94
DAFNA Capital Management
California
$1.96M -$3.17M -340,000 -61%
ECM
95
ExodusPoint Capital Management
New York
$1.89M +$1.4M +149,907 +246%
HSA
96
Hussman Strategic Advisors
Maryland
$1.88M -$978K -105,000 -33%
ACM
97
Aquatic Capital Management
Illinois
$1.86M +$1.93M +207,774 New
GAM
98
Gotham Asset Management
New York
$1.81M +$1.47M +157,749 +358%
Principal Financial Group
99
Principal Financial Group
Iowa
$1.69M +$1.6M +171,701 +1,041%
California State Teachers Retirement System (CalSTRS)
100
California State Teachers Retirement System (CalSTRS)
California
$1.63M +$30.9K +3,313 +2%
2 3
4
5 6

BCRX Hedge Fund Activity: Q2 2025 in Review

294 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2025, worth a combined $1.77B — up 34% from $1.32B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new BCRX positions and 30 closed out — a net gain of 22 holders — while 113 added to existing stakes and 85 trimmed.

The largest buyer was Arrowstreet Capital, adding an estimated $38M. The largest seller was Avoro Capital Advisors, cutting an estimated $39.1M.

  • 294 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2025, up from 274 in Q1 2025.
  • Funds reported $1.77B of BioCryst Pharmaceuticals stock for Q2 2025, up 34% quarter-over-quarter.
  • 52 funds opened new BioCryst Pharmaceuticals positions in Q2 2025 and 30 closed out, a net change of +22 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q2 2025 was Arrowstreet Capital, an estimated $38M added.
  • The largest BioCryst Pharmaceuticals seller in Q2 2025 was Avoro Capital Advisors, an estimated $39.1M sold.

Based on aggregated 13F filings for Q2 2025.